News
GLPGF
35.15
NaN%
--
Lakefront Biotherapeutics Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 3d ago
Lakefront Biotherapeutics initiates new €50M share repurchase program
Seeking Alpha · 4d ago
Abivax: Safety Signals Loom Ahead Of The NDA Submission
Seeking Alpha · 06/18 10:53
Galapagos NV, Gilead Sciences strike deal tied to Ouro Medicines acquisition
Seeking Alpha · 03/31 05:48
Tracking David Einhorn's Greenlight Capital Portfolio - Q4 2025 Update
Seeking Alpha · 03/23 00:09
Galapagos GAAP EPS of €4.87, revenue of €1.11B; introduces Q1 and FY26 outlook
Seeking Alpha · 02/24 04:32
Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation
Seeking Alpha · 12/22/2025 10:39
Tracking David Einhorn's Greenlight Capital Portfolio - Q3 2025 Update
Seeking Alpha · 12/15/2025 04:48
More
Webull provides a variety of real-time GLPGF stock news. You can receive the latest news about Lakefront Biotherapeutics through multiple platforms. This information may help you make smarter investment decisions.
About GLPGF
Lakefront Biotherapeutics NV is a Belgium‑based company. The Company develops medicines for patients with serious diseases in areas of unmet medical need and uses deal‑making capabilities and capital to identify, acquire, and advance opportunities that create value for patients and shareholders. Its pipeline includes clinical‑stage immunology and oncology programs, such as autoimmune disease candidates and selected oncology assets, primarily advanced through partnerships and targeted development rather than in‑house cell therapy platforms. It builds a portfolio of clinical‑stage therapies intended to support existing treatment approaches and operates across oncology and immunology and inflammation programs supported by clinical proof of concept in emerging therapeutic areas.